| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1025124406 |
| P356 | DOI | 10.1186/1741-7015-10-28 |
| P932 | PMC publication ID | 3334713 |
| P698 | PubMed publication ID | 22436374 |
| P5875 | ResearchGate publication ID | 221902972 |
| P50 | author | Jacques De Greve | Q58132858 |
| Ijeoma Adaku Umelo | Q59705430 | ||
| P2093 | author name string | Gang Chen | |
| Erik Teugels | |||
| Peter Kronenberger | |||
| P2860 | cites work | KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib | Q21563446 |
| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 | ||
| A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours | Q24653999 | ||
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity | Q27644014 | ||
| Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer | Q43297707 | ||
| A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy | Q43920708 | ||
| A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer | Q44290350 | ||
| Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. | Q45004003 | ||
| Assessment of erlotinib in chemoresponse assay. | Q45968211 | ||
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. | Q46027726 | ||
| Development of quantitative molecular clinical end points for siRNA clinical trials | Q46205464 | ||
| Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. | Q46502833 | ||
| Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. | Q46672565 | ||
| siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma | Q46707269 | ||
| Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study | Q46720863 | ||
| Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. | Q51776233 | ||
| Zero interaction response surfaces for combined-action assessment. | Q64948214 | ||
| Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer | Q27851396 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR | Q28240702 | ||
| Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles | Q29615957 | ||
| Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies | Q29616780 | ||
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
| The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. | Q30871179 | ||
| Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers. | Q33731181 | ||
| BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. | Q34014866 | ||
| Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells. | Q34618082 | ||
| Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy | Q34701196 | ||
| Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors | Q35116206 | ||
| Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer | Q35177848 | ||
| American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. | Q35613883 | ||
| Current progress of siRNA/shRNA therapeutics in clinical trials | Q36071638 | ||
| Clinical implications of the mechanism of epidermal growth factor receptor inhibitors | Q36565941 | ||
| Modeling oncogene addiction using RNA interference. | Q36840172 | ||
| Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. | Q36882696 | ||
| Biology of interactions: antiepidermal growth factor receptor agents | Q36935078 | ||
| Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer | Q37363050 | ||
| Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck | Q37536418 | ||
| EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. | Q37767383 | ||
| KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q38432430 | ||
| Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor | Q39695840 | ||
| Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction | Q39766892 | ||
| Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors | Q39773474 | ||
| Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations | Q39813855 | ||
| A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival | Q39845869 | ||
| Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines | Q39872383 | ||
| Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. | Q39925893 | ||
| Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. | Q40026514 | ||
| Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study | Q40070060 | ||
| Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. | Q40133869 | ||
| An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. | Q40384809 | ||
| Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins | Q40396742 | ||
| Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. | Q40400258 | ||
| Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. | Q40505812 | ||
| Modulation of Janus kinase 2 by p53 in ovarian cancer cells | Q40517172 | ||
| Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. | Q41170117 | ||
| Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors | Q42948964 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | RNA interference | Q201993 |
| cetuximab | Q420296 | ||
| non-small-cell lung carcinoma | Q3658562 | ||
| P304 | page(s) | 28 | |
| P577 | publication date | 2012-03-21 | |
| P1433 | published in | BMC Medicine | Q4835947 |
| P1476 | title | Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab | |
| P478 | volume | 10 |
| Q33776664 | A Combined ULBP2 and SEMA5A Expression Signature as a Prognostic and Predictive Biomarker for Colon Cancer |
| Q33605906 | A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer |
| Q35671176 | Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas |
| Q42593919 | Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter |
| Q36341433 | Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems |
| Q52655265 | Afatinib in advanced NSCLC: a profile of its use. |
| Q39016290 | Afatinib: A Review in Advanced Non-Small Cell Lung Cancer |
| Q38179266 | Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer |
| Q38132049 | Afatinib: first global approval |
| Q36088484 | An Encapsulation of Gene Signatures for Hepatocellular Carcinoma, MicroRNA-132 Predicted Target Genes and the Corresponding Overlaps |
| Q28729071 | Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells |
| Q62636307 | Antitumor Monoterpenes |
| Q53367071 | Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients. |
| Q35776681 | Association between underexpression of microrna-203 and clinicopathological significance in hepatocellular carcinoma tissues |
| Q33870539 | Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo |
| Q47193804 | Clinical role and biological function of CDK5 in hepatocellular carcinoma: A study based on immunohistochemistry, RNA-seq and in vitro investigation |
| Q60302022 | Clinical significance and effect of MTDH/AEG-1 in bladder urothelial cancer: a study based on immunohistochemistry, RNA-seq, and in vitro verification |
| Q38794742 | Clinical value of miR-452-5p expression in lung adenocarcinoma: A retrospective quantitative real-time polymerase chain reaction study and verification based on The Cancer Genome Atlas and Gene Expression Omnibus databases |
| Q36729248 | Clinicopathological significance of STAT4 in hepatocellular carcinoma and its effect on cell growth and apoptosis |
| Q36299606 | Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade |
| Q89471602 | Correction to: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab |
| Q53576820 | Correlation between down-expression of miR-431 and clinicopathological significance in HCC tissues. |
| Q34645417 | Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues |
| Q37708836 | Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors |
| Q35961790 | Down-Regulation of MiR-193a-3p Dictates Deterioration of HCC: A Clinical Real-Time qRT-PCR Study |
| Q36010194 | Downregulation of MiR-30a is Associated with Poor Prognosis in Lung Cancer |
| Q89868682 | Downregulation of miR-193a-3p is involved in the pathogenesis of hepatocellular carcinoma by targeting CCND1 |
| Q37238128 | Downregulation of miR-219 enhances brain-derived neurotrophic factor production in mouse dorsal root ganglia to mediate morphine analgesic tolerance by upregulating CaMKIIγ. |
| Q37634419 | Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma |
| Q47225780 | Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15. |
| Q37564156 | Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues |
| Q35927282 | Expression and clinicopathological significance of miR-193a-3p and its potential target astrocyte elevated gene-1 in non-small lung cancer tissues |
| Q64120000 | Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway |
| Q34205467 | Imaging of epidermal growth factor receptor on single breast cancer cells using surface-enhanced Raman spectroscopy |
| Q34548464 | Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro |
| Q36806950 | Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy |
| Q35837786 | Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer |
| Q38669280 | Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update |
| Q35537955 | MiR-133a is downregulated in non-small cell lung cancer: a study of clinical significance |
| Q35925686 | MiR-30a-5p suppresses cell growth and enhances apoptosis of hepatocellular carcinoma cells via targeting AEG-1. |
| Q26866521 | Non-coding RNAs in lung cancer |
| Q46700376 | RETRACTED: Ca(2+)/calmodulin-dependent protein kinase IIγ, a critical mediator of the NF-κB network, is a novel therapeutic target in non-small cell lung cancer |
| Q45154939 | Recent therapeutic breakthroughs in respiratory medicine |
| Q36193083 | Roadmap to personalized medicine |
| Q48070194 | Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation |
| Q33660974 | Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells. |
| Q34635475 | Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib |
| Q38800568 | Targeting non-canonical autophagy overcomes erlotinib resistance in tongue cancer |
| Q51060657 | Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells. |
| Q35425128 | The non-coding RNAs of the H19-IGF2 imprinted loci: a focus on biological roles and therapeutic potential in Lung Cancer |
| Q34674537 | Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET |
| Q92382383 | Upregulated miRNA-182-5p expression in tumor tissue and peripheral blood samples from patients with non-small cell lung cancer is associated with downregulated Caspase 2 expression |
| Q58779335 | Upregulation of HOXA11 during the progression of lung adenocarcinoma detected via multiple approaches |
| Q34653749 | miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells |
| Q27022043 | siRNA delivery to the lung: what's new? |
Search more.